financetom
Business
financetom
/
Business
/
US banks rise as Fed stress test success clears path for payouts
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US banks rise as Fed stress test success clears path for payouts
Jun 30, 2025 2:56 AM

(Reuters) -Wall Street's biggest banks rose in premarket trading on Monday after sailing through the Federal Reserve's annual health check, setting the stage for billions in stock buybacks and dividends.

The central bank said on Friday that 22 of the largest U.S. banks were well-positioned to withstand a future economic downturn and continue lending, with its stress test showing firms maintained strong capital levels even after incurring hundreds of billions of dollars in losses.

The results are a strong sign that U.S. lenders are in good shape even amid heightened economic uncertainty, helping government officials and investors understand if banks can continue lending money even during a crisis.

Passing the stress test also gives banks the green light to proceed with shareholder payouts, including dividends and buybacks.

"All the participant banks passed the stress test (which was not a surprise), and this lends support to our view that they remain well positioned to return capital should they so choose," analysts at brokerage RBC Capital Markets said.

Shares of Bank of America rose 1.1% before the opening bell. Rivals JPMorgan Chase, Citigroup and Wells Fargo added between 0.5% and 2%.

Investment banks Morgan Stanley and Goldman Sachs were up 0.4% and 2.5%, respectively.

Banks did better in the 2025 stress test compared to 2024, partly because this year's test was less stringent. The test simulates an economy in crisis, so since the real economy was already a bit weaker before the test, the scenario ended up being less severe.

"In general, the results were positive across the board and supportive of an improving capital return backdrop for all participants," Jefferies analysts wrote in a note, adding that stress capital buffers will not be finalized until August, and banks may still have room to adjust dividend increases.

The 2025 test involved a severe global recession that included a 30% decline in commercial real estate prices and a 33% decline in home prices. The unemployment rate spiked 5.9 percentage points to 10% under the test.

The Federal Reserve rolled out its Dodd-Frank stress tests in 2011 to gauge whether the biggest U.S. banks could weather a sharp economic downturn, aiming to prevent a repeat of the 2008 financial crisis.

Banks have long pushed back against the exercise, arguing that it is overly complex, costly to conduct and restricts capital returns even when firms are financially sound.

The S&P 500 Banks Index, which tracks large-cap banks, has risen about 12% so far this year through the previous close, outpacing a 5% gain in the benchmark S&P 500.

(Reporting by Manya Saini in Bengaluru; Editing by Saumyadeb Chakrabarty)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Catalent Fiscal Q4 Adjusted Earnings, Net Revenue Climb
Catalent Fiscal Q4 Adjusted Earnings, Net Revenue Climb
Aug 29, 2024
08:08 AM EDT, 08/29/2024 (MT Newswires) -- Catalent ( CTLT ) reported fiscal Q4 adjusted earnings Thursday of $0.65 per diluted share, up from $0.02 a year earlier. Analysts polled by Capital IQ expected $0.56. Net revenue for the quarter ended June 30 was $1.3 billion, up from $1.06 billion a year earlier. Analysts polled by Capital IQ expected $1.24...
XORTX Surges 62% in U.S. Premarket as Peer-Reviewed Research Backs Company's Approach to Polycystic Kidney Disease
XORTX Surges 62% in U.S. Premarket as Peer-Reviewed Research Backs Company's Approach to Polycystic Kidney Disease
Aug 29, 2024
08:09 AM EDT, 08/29/2024 (MT Newswires) -- XORTX Therapeutics ( XRTX ) jumped 62% on Thursday in New York premarket trading after the company said that recent peer-reviewed, independent, published research shows genetic factors are linked to the over-expression of xanthine oxidase (XO) and play a role in several diseases, including kidney disease. The findings support the company's approach to...
Kanzhun's Board Approves New $150 Million Share Repurchase Program
Kanzhun's Board Approves New $150 Million Share Repurchase Program
Aug 29, 2024
08:09 AM EDT, 08/29/2024 (MT Newswires) -- Kanzhun ( BZ ) said Thursday that the company's board of directors has authorized a new $150 million share repurchase program, starting Aug. 29 for 12 months. The new program will operate together with the existing $200 million share repurchase program that became effective on Mar. 20 for 12 months, the company said....
ECARX Partners With MulticoreWare to Optimize Advanced Driving Platforms
ECARX Partners With MulticoreWare to Optimize Advanced Driving Platforms
Aug 29, 2024
08:12 AM EDT, 08/29/2024 (MT Newswires) -- ECARX Holdings ( ECX ) said Thursday it has partnered with MulticoreWare to collaborate on improving algorithms for its automated driving platforms. ECARX ( ECX ) and MulticoreWare will work to improve the response times and accuracy of intelligent driving systems and speed up the production process of the platforms. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved